Related Experiment Videos
Multiple Myeloma: An Overview in 1996
Kyle1
1Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905, USA.
The Oncologist
|January 1, 1996
Summary
Multiple myeloma (MM) is a cancer diagnosed by M-protein levels and plasma cell counts. Differentiating MM from SMM and MGUS relies on PCLI and circulating plasma cells, impacting treatment and prognosis.
Area of Science:
- Hematology
- Oncology
Background:
- Multiple myeloma (MM) affects approximately 4 in 100,000 individuals annually.
- Monoclonal (M-) protein is present in 99% of MM patients during their disease course.
- Distinguishing MM from smoldering multiple myeloma (SMM) is crucial for appropriate management.
Purpose of the Study:
- To outline diagnostic criteria for multiple myeloma.
- To differentiate MM from SMM and monoclonal gammopathy of undetermined significance (MGUS).
- To review current treatment modalities and their associated survival rates.
Main Methods:
- Diagnostic criteria for MM, SMM, and MGUS are defined.
- Plasma cell labeling index (PCLI) and circulating plasma cells are discussed as key diagnostic markers.
- Treatment outcomes for chemotherapy, allogeneic, and autologous stem cell transplantation are reviewed.
Main Results:
- Low PCLI and beta-2-microglobulin levels correlate with a median survival of approximately six years.
- Melphalan and prednisone yield a 50-60% response rate.
- While stem cell transplantation shows higher response rates, most patients eventually relapse.
Conclusions:
- Accurate differentiation of MM, SMM, and MGUS is essential for patient prognosis.
- Current treatments offer limited long-term survival, highlighting the need for novel therapeutic strategies.
- Autologous stem cell transplantation offers improved outcomes but does not eliminate the risk of relapse.